HTG Molecular Diagnostics Company Profile (NASDAQ:HTGM)

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) issued its earnings results on Tuesday, August, 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.60). The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. View HTG Molecular Diagnostics' Earnings History.

HTG Molecular Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for HTG Molecular Diagnostics.

3 equities research analysts have issued 1-year price targets for HTG Molecular Diagnostics' stock. Their forecasts range from $6.00 to $6.50. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $6.17 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.

Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:

• 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (8/15/2017)
• 2. HC Wainwright analysts commented, "We note that the launch of this new assay comes on schedule and expands the company’s existing menu following the launch of HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assays for research use. Investors may recall that this assay was designed for retrospective gene expression profiling (GEP) to complement traditional immunohistochemistry (IHC) testing, allowing investigators to assess mRNA expression of large numbers of biomarkers—up to 470 mRNA targets in this case—when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. Importantly, small and minimally invasive tissue biopsies are the trend nowadays in diagnostics, and within this setting, EdgeSeq PATH Assay allows for a more comprehensive profiling than conventional IHC. This may potentially lead to new GEP-based diagnostic or prognostic tests in oncology and beyond, in our view." (6/29/2017)

HTG Molecular Diagnostics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,505,393 shares, an increase of 27.3% from the July 14th total of 1,182,654 shares. Based on an average daily trading volume, of 321,258 shares, the short-interest ratio is currently 4.7 days. Approximately 25.6% of the shares of the company are short sold.

Some companies that are related to HTG Molecular Diagnostics include Akari Therapeutics PLC (AKTX), Imprimis Pharmaceuticals (IMMY), Biolase (BIOL), ContraVir Pharmaceuticals (CTRV), Chiasma (CHMA), CareDx (CDNA), KemPharm (KMPH), SCYNEXIS (SCYX), Presbia PLC (LENS), pSivida Corp. (PSDV), Bellerophon Therapeutics (BLPH), Ekso Bionics Holdings (EKSO), Histogenics Corporation (HSGX), Evoke Pharma (EVOK), Orexigen Therapeutics (OREX), Microbot Medical (MBOT), TRACON Pharmaceuticals (TCON) and Fibrocell Science (FCSC).

HTG Molecular Diagnostics' management team includes the folowing people:

• Ann F. Hanham Ph.D., Independent Chairman of the Board
• Timothy B. Johnson, President, Chief Executive Officer, Director
• Shaun D. McMeans, Vice President of Finance and Administration, Chief Financial Officer
• Patrick C. Roche Ph.D., Senior Vice President - Research and Product Development
• Debra A. Gordon Ph.D. J.D., Vice President, Chief Legal Counsel and Secretary
• John L. Lubniewski, Chief Business Officer
• Donnie M. Hardison, Director
• Harry A. George, Independent Director
• James T. LaFrance, Independent Director
• Lee Roy McCracken, Independent Director

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

HTG Molecular Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include NOVO HOLDINGS A (12.03%), GLAXOSMITHKLINE PLC (8.30%), FMR LLC (7.07%) and Vanguard Group Inc. (1.42%). Company insiders that own HTG Molecular Diagnostics stock include Debra A Gordon, John L Lubniewski, Patrick C Roche, Plc Glaxosmithkline, Shaun D Mcmeans and Tim B Johnson. View Institutional Ownership Trends for HTG Molecular Diagnostics.

HTG Molecular Diagnostics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for HTG Molecular Diagnostics.

Shares of HTG Molecular Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTG Molecular Diagnostics stock can currently be purchased for approximately $2.09.